Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

moneytome Apr. 2 at 7:59 PM

$SCYX nice setup here! Looking for a break up next week. $CRDL next week probably will take a breather before next leg up. $TCRX be patient!

0 · Reply

NoBox Apr. 2 at 3:41 PM

$TCRX Insiders jumping ship. https://www.investing.com/news/sec-filings/tscan-therapeutics-announces-resignation-of-vice-president-of-finance-93CH-4595264

0 · Reply

suredubb Mar. 31 at 4:29 PM

$TCRX the hematology conference next week is in Asia.. not sure if tcrx are there EHA conference in June they will present… should get updates at their next presentation ASH in December they will present

0 · Reply

suredubb Mar. 31 at 2:05 PM

$TCRX they have a healthcare conference next week on april 8th.. good chance they update there… they said in early March that results are positive to this point

0 · Reply

suredubb Mar. 30 at 2:28 PM

$TCRX recently presented positive data.. more updates in Q2 and 2nd half 2026 good time to get in

0 · Reply

suredubb Mar. 30 at 1:03 AM

$TCRX strong support base for almost 6 months… cash until end of 2027 great time to scale in

0 · Reply

ducruacuteo11 Mar. 29 at 4:08 PM

$TCRX the more i perform dd on this, i really like their chance of success. Wonder why they are sitting at $1.X or below?

1 · Reply

soddo40725 Mar. 27 at 4:24 PM

$TCRX OINK OINK

0 · Reply

moneytome Mar. 27 at 2:27 PM

$TCRX adding here. $CRDL breakout

0 · Reply

suredubb Mar. 27 at 1:58 PM

$TCRX price action is accumulation… chart has super string base going to blow great time to scale in

0 · Reply

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 7:00 AM EST - 5 weeks ago

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Dec 3, 2025, 4:05 PM EST - 4 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Nov 12, 2025, 7:00 AM EST - 5 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 5 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 6:30 AM EST - 5 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 7 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 3, 2025, 7:00 AM EDT - 7 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 8 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 6, 2025, 7:00 AM EDT - 11 months ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 7, 2025, 11:31 AM EST - 1 year ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 10, 2025, 3:14 AM EST - 1 year ago

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Aug 26, 2024, 10:09 AM EDT - 1 year ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 2 years ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

moneytome Apr. 2 at 7:59 PM

$SCYX nice setup here! Looking for a break up next week. $CRDL next week probably will take a breather before next leg up. $TCRX be patient!

0 · Reply

NoBox Apr. 2 at 3:41 PM

$TCRX Insiders jumping ship. https://www.investing.com/news/sec-filings/tscan-therapeutics-announces-resignation-of-vice-president-of-finance-93CH-4595264

0 · Reply

suredubb Mar. 31 at 4:29 PM

0 · Reply

suredubb Mar. 31 at 2:05 PM

$TCRX they have a healthcare conference next week on april 8th.. good chance they update there… they said in early March that results are positive to this point

0 · Reply

suredubb Mar. 30 at 2:28 PM

$TCRX recently presented positive data.. more updates in Q2 and 2nd half 2026 good time to get in

0 · Reply

suredubb Mar. 30 at 1:03 AM

$TCRX strong support base for almost 6 months… cash until end of 2027 great time to scale in

0 · Reply

ducruacuteo11 Mar. 29 at 4:08 PM

$TCRX the more i perform dd on this, i really like their chance of success. Wonder why they are sitting at $1.X or below?

1 · Reply

soddo40725 Mar. 27 at 4:24 PM

$TCRX OINK OINK

0 · Reply

moneytome Mar. 27 at 2:27 PM

$TCRX adding here. $CRDL breakout

0 · Reply

suredubb Mar. 27 at 1:58 PM

$TCRX price action is accumulation… chart has super string base going to blow great time to scale in

0 · Reply

nshootz Mar. 23 at 7:46 PM

$TCRX I like the action here... accumulation. Watch for stop-loss raids in the next 1-2 months

0 · Reply

soddo40725 Mar. 23 at 1:34 PM

$TCRX PIG

0 · Reply

suredubb Mar. 17 at 5:00 PM

$TCRX Picked up 16,000 shares at 1.10 i love early stage bio.. 5x-10x in a year good time to scale in

1 · Reply

soddo40725 Mar. 13 at 8:46 PM

$TCRX lot's of trades AH

0 · Reply

OfficialStocktwitsUser Mar. 13 at 3:40 PM

$TCRX RSI: 56.76, MACD: 0.0267 Vol: 0.07, MA20: 1.07, MA50: 1.08 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply